European Commission Expands Tecvayli-Daratumumab to Second-Line Multiple Myeloma
The European Commission has expanded the approval of Johnson & Johnson’s teclistamab (Tecvayli), a BCMA-targeted bispecific antibody, in combination with daratumumab, to patients with relapsed or refractory multiple myeloma who have received at least…
